BPC-157 and TB-500 together

BPC-157 and TB-500 are almost never studied apart from each other — and never studied together. Here's what the rodent data on each compound actually shows, why people stack them anyway, and what the evidence gap means before you consider it.

BPC-157 and TB-500 show up together so often in recovery circles that the combination has its own nickname — the "Wolverine stack," after the self-healing comic-book mutant. The pairing sounds like it should work: one peptide is best known for gut and connective-tissue healing in rodent studies, the other for driving cell migration into a wound. But strip away the branding and one fact holds for both compounds individually, and doubly for the pair: neither has completed a published human clinical trial, and no one has ever run a controlled study of the two together, in animals or in people.⁸ Everything below separates what's actually been measured in a lab from what's been extrapolated by people stacking the two at home.

What BPC-157 and TB-500 actually are

BPC-157 is a synthetic 15-amino-acid fragment (GEPPPGKPADDAGLV) modeled on a sequence identified in human gastric juice. It's been studied almost exclusively by one research group at the University of Zagreb since the 1990s, mostly in rat models of tendon, ligament, and gut healing, where it appears to upregulate VEGF-driven blood-vessel growth in injured tissue.¹² See our full BPC-157 profile for the mechanism and dosing detail in depth.

TB-500 is marketed as a synthetic version of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein that's the primary actin-sequestering molecule in most cells³ — it binds free actin monomers and, in doing so, regulates a cell's ability to build the internal scaffolding it needs to migrate toward a wound.⁴ That's a nuance most vendor pages skip: the bulk of the published wound-healing, corneal, cardiac, and angiogenesis research was done on full-length Tβ4⁴⁵⁶⁷ — not on the shorter synthetic fragment (built around Tβ4's actin-binding sequence, LKKTETQ) that's actually sold under the name "TB-500." Whether the two behave identically in the body has never been directly tested; it's an assumption carried over from the parent molecule's research, not a confirmed equivalence. Our TB-500 profile has the full breakdown.

Why they're stacked together: the theory

The stacking logic is mechanistic, not clinical. BPC-157's best-documented rodent effect is upregulating VEGF and growth-hormone-receptor expression in injured tissue — recruiting blood supply and growth-factor signaling to the injury site.¹ Tβ4/TB-500's best-documented effect is mobilizing cell migration by controlling the actin cytoskeleton — helping the cells that do the repairing (fibroblasts, keratinocytes, endothelial and progenitor cells) physically move into the wound.³⁴⁵ On paper, one recruits the resources and the other moves the workforce. That's a coherent hypothesis built from two separate bodies of rodent literature — but it has never been tested as a combination, in any species, in a controlled study.⁸ Every claim about the two working "better together" is an inference, not a finding.

The evidence base: rodent data on each, none on the pair

Individually, each compound has a real — if narrow — preclinical record. BPC-157 has shown improved healing in rat models of Achilles tendon transection, ligament rupture, and surgical gut anastomosis.¹² Full-length Tβ4 accelerated wound closure by as much as 61% over controls in a rat full-thickness skin-wound model,⁴ reduced inflammation and improved healing after alkali burns to the cornea in rabbits,⁶ promoted angiogenesis and hair-follicle development in aged rodents,⁷ and — in one of the more cited results — activated a cell-survival pathway (integrin-linked kinase, Akt) that improved cardiac cell migration and heart repair after induced myocardial infarction in mice.⁵

None of that is human evidence, and none of it is combination evidence. A 2026 scoping review of the Tβ4/TB-500 and BPC-157 literature found the same gap this article is built around: a substantial, replicated rodent evidence base for each compound on its own, and no registered or published controlled trial of the stack in any species.⁸ Search clinicaltrials.gov for the combination and you'll find nothing — because nothing has been run.

Community dosing patterns for the stack (not a prescription)

No dosing protocol for this combination comes from a clinical trial — there isn't one to draw from. The numbers below are what's commonly repeated across peptide forums, vendor dosing charts, and community write-ups, generally extrapolated from each compound's individual rodent-derived dosing logic rather than any human pharmacokinetic study. Treat this as a description of common practice, not a recommendation.

Reconstituting either peptide follows the same bacteriostatic-water process as any other lyophilized peptide — our step-by-step injection guide covers reconstitution ratios, drawing the correct dose, and subcutaneous technique in detail. Because the two compounds are dosed in different units (BPC-157 typically in micrograms, TB-500 in milligrams) from different-strength vials, use a dose calculator rather than mental math when converting between mg, mcg, and syringe units — a single decimal-point error is an easy way to 10x a dose.

Cycle length and timing

Community protocols for TB-500 typically describe a "loading" phase of 4–6 weeks at the higher end of the range, followed by a lower-dose maintenance phase or a break — loosely borrowed from the idea that Tβ4's short elimination half-life (minutes, based on animal pharmacokinetics) means tissue effects depend on sustained, repeated dosing rather than a single application.⁴ BPC-157 protocols are more often run continuously for 4–8 weeks alongside the injury being addressed, then stopped. None of these cycle lengths have been validated in a controlled study of any duration — they're pattern-matched from how the individual rodent studies dosed the animals, adapted to a human schedule by the community, not derived from a trial that measured outcomes at different cycle lengths.

Reported side effects and unknowns

Because there's no completed human trial for either compound, there's no formal side-effect profile the way there is for an FDA-approved drug. In the rodent literature, both compounds are generally described as well tolerated at the doses tested over the (short) study durations used — but "no toxicity observed in a several-week rat study" is a much weaker safety statement than a phase 3 human trial with a published adverse-event table.¹⁴ Informally, people using the stack report injection-site irritation and occasional flushing, lightheadedness, or fatigue after dosing — none of it systematically tracked or published. Longer-term unknowns are genuinely unknown: whether pairing two pro-angiogenic, tissue-growth-signaling compounds changes that risk profile compared to either alone hasn't been studied in any species. Anyone with a personal or family history of cancer should treat that specific gap seriously and discuss it with a clinician before starting.

1. No human pharmacokinetic data for either compound, so dosing intervals and "steady state" claims are extrapolated from rodent metabolism, not measured in people.
2. No published data on how the two compounds interact when dosed together — whether effects are additive, redundant, or something else entirely.
3. Purity and sourcing risk compounds the uncertainty: research-use vials aren't manufactured to pharmaceutical standards, so a batch's actual content can differ from its label.
4. No adverse-event reporting pathway comparable to FDA MedWatch exists for either compound, so real-world harm patterns — if they exist — surface slowly, if at all.

Legal status and sourcing risk

Neither compound is FDA-approved for any use. Both are currently under active FDA review: a Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24, 2026 is set to evaluate BPC-157 and TB-500 — alongside KPV and MOTS-c — as candidates for the Section 503A compounding bulks list, with TB-500 specifically nominated for a wound-healing indication.⁹ That review was still pending as of this writing; nothing has been finalized, and the outcome could move either compound's compounding status in either direction. Outside a compounding pharmacy, what's sold online as "BPC-157" or "TB-500" is explicitly labeled research-use-only — not legal to market for human use, and manufactured with no FDA oversight of what's actually in the vial.

If you compete in a sport tested under World Anti-Doping Agency rules, this is a separate and simpler line: TB-500/Tβ4 is listed by name, and BPC-157-type healing peptides fall under the same category, in section S2 (peptide hormones, growth factors and related substances) of the WADA Prohibited List — banned at all times, not just on competition day, and enforceable even without a positive test, based on records or admissions of use.¹⁰

The bottom line

BPC-157 and TB-500 are two of the better-studied preclinical peptides — "better studied" meaning a genuine, replicated rodent literature, not a human one. The mechanistic case for stacking them is coherent: different steps of the same repair cascade, on paper. But a coherent theory and a tested protocol are different things, and right now the combination sits entirely in the first category. If you do decide to log a stack rather than a single compound, keep both doses, timings, and any side effects on one running record rather than trying to remember which peptide did what later — that's the difference between a real data point and a guess after the fact. Read the are peptides safe guide before starting anything in the preclinical tier; this article and this site are general information, not medical advice — talk to a licensed clinician about your specific situation.

FAQ

References

Primary sources — PubMed / NEJM / The Lancet.

1. Brcic L, Brcic I, Staresinic M, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009. https://pubmed.ncbi.nlm.nih.gov/20388964/
2. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. https://pubmed.ncbi.nlm.nih.gov/20225319/
3. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. https://pubmed.ncbi.nlm.nih.gov/16099219/
4. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. https://pubmed.ncbi.nlm.nih.gov/10469335/
5. Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. https://pubmed.ncbi.nlm.nih.gov/15565145/
6. Sosne G, Szliter EA, Barrett R, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293-299. https://pubmed.ncbi.nlm.nih.gov/11950239/
7. Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. https://pubmed.ncbi.nlm.nih.gov/15037013/
8. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review. Applied Sciences (MDPI). 2026. https://www.mdpi.com/2076-3417/16/12/6202
9. U.S. Food and Drug Administration / Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting — Bulk Drug Substances Nominated for Inclusion on the Section 503A List (BPC-157, KPV, TB-500, MOTS-c). April 16, 2026. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
10. World Anti-Doping Agency. The Prohibited List — S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA. 2026. https://www.wada-ama.org/en/prohibited-list